RAYMOND CHO: Open Payments
NPI 1700859238 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 20 payments from 9 companies in 2025. Trend: 2023 $2,299 · 2024 $780 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $270 |
| ABBVIE INC. | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: COBENFY, VRAYLAR, SPRAVATO, REXULTI, FANAPT, INGREZZA, INVEGA SUSTENNA, CAPLYTA.
Industry payments across TX — which companies pay providers there.
